+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Dermatology Drugs Market by Therapeutic Class, Route of Administration, Indication Type, End-User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967940
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Dermatology Drugs Market grew from USD 31.40 billion in 2023 to USD 34.23 billion in 2024. It is expected to continue growing at a CAGR of 9.83%, reaching USD 60.56 billion by 2030.

The Dermatology Drugs market encompasses a wide range of pharmaceuticals designed to treat skin conditions such as acne, psoriasis, eczema, and skin infections. This market's scope includes topical creams, oral medications, and injectable drugs, each catering to different dermatological needs and severity levels. With rising incidences of skin conditions globally and an increasing demand for aesthetic enhancements, the necessity and application of dermatology drugs have expanded. The primary end-users are hospitals, dermatology clinics, and homecare settings, which increasingly rely on innovative treatments to enhance patient outcomes. Market growth is significantly influenced by factors such as increasing awareness about skin health, advancements in biotechnology that allow for more targeted therapies, and a surge in disposable incomes boosting expenditures on skincare. Furthermore, the growing geriatric population, prone to skin ailments, contributes to market expansion. However, potential opportunities exist in the form of personalized medicine and the development of biologics targeting specific skin conditions, with a particular focus on treatments that minimize side effects. Companies can capitalize on these opportunities by investing in R&D capabilities and forming strategic partnerships with biotech firms. Challenges in this market include regulatory hurdles, high costs associated with R&D, and stringent approval processes that can delay product launches. Additionally, the market faces pricing pressures due to generic competition and healthcare cost containment efforts. The best areas for innovation are in the development of combination therapies, digital dermatology tools such as AI-powered diagnostics, and sustainable formulations that cater to the increasing consumer demand for eco-friendly products. The market's nature remains dynamic and highly competitive, driven by both technological advancements and consumer preferences. Companies aiming for business growth should focus on expanding their product pipelines, enhancing their global market presence, and aligning with evolving regulatory standards to ensure compliance and competitiveness.

Understanding Market Dynamics in the Dermatology Drugs Market

The Dermatology Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
    • Technological advancements in drug development, along with a strong pipeline of dermatological drugs
    • Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
  • Market Restraints
    • Stringent and time-consuming regulatory approval process
  • Market Opportunities
    • Emerging investment in personalized medicine, and rising application in telemedicine
    • Notable shift towards natural and organic ingredients in dermatological products
  • Market Challenges
    • High treatment costs and stringent regulatory policy

Exploring Porter’s Five Forces for the Dermatology Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Dermatology Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dermatology Drugs Market

External macro-environmental factors deeply influence the performance of the Dermatology Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dermatology Drugs Market

The Dermatology Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dermatology Drugs Market

The Dermatology Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dermatology Drugs Market

The Dermatology Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dermatology Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc by Abbvie Inc., Almirall S.A., Amgen Inc., Arcutis Biotherapeutics, Inc., Asterisk Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited, DermBiont, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., GlaxoSmithkline plc, Johnson & Johnson Services, Inc., Leo Pharma A/S, Lupin Ltd, Mayne Pharma Group Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc., Roivant Sciences Ltd., and Shinom Cosmeceuticals.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutic Class
    • Antifungals
    • Corticosteroids
    • Immunosuppressants
    • Retinoids
  • Route of Administration
    • Oral
    • Parenteral Injection
    • Topical
  • Indication Type
    • Acne
    • Atopic dermatitis
    • Psoriasis
    • Skin cancer
  • End-User
    • Aesthetic & Dermatology Clinics
    • Diagnostic Centers & Laboratories
    • Hospitals
  • Distribution Channel
    • Hospital pharmacies
    • Retail pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
5.1.1.2. Technological advancements in drug development, along with a strong pipeline of dermatological drugs
5.1.1.3. Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
5.1.2. Restraints
5.1.2.1. Stringent and time-consuming regulatory approval process
5.1.3. Opportunities
5.1.3.1. Emerging investment in personalized medicine, and rising application in telemedicine
5.1.3.2. Notable shift towards natural and organic ingredients in dermatological products
5.1.4. Challenges
5.1.4.1. High treatment costs and stringent regulatory policy
5.2. Market Segmentation Analysis
5.2.1. Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions
5.2.2. End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dermatology Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Antifungals
6.3. Corticosteroids
6.4. Immunosuppressants
6.5. Retinoids
7. Dermatology Drugs Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral Injection
7.4. Topical
8. Dermatology Drugs Market, by Indication Type
8.1. Introduction
8.2. Acne
8.3. Atopic dermatitis
8.4. Psoriasis
8.5. Skin cancer
9. Dermatology Drugs Market, by End-User
9.1. Introduction
9.2. Aesthetic & Dermatology Clinics
9.3. Diagnostic Centers & Laboratories
9.4. Hospitals
10. Dermatology Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital pharmacies
10.3. Retail pharmacies
11. Americas Dermatology Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Dermatology Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Dermatology Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Almirall and Microsoft announce partnership for the development of novel treatments for skin diseases
14.3.2. FDA Approves Arcutis’ ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis
14.3.3. Eli Lilly forays into dermatological space with launch of psoriasis drug
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. DERMATOLOGY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DERMATOLOGY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 45. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 72. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 74. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 77. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 87. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 89. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 117. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 119. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 133. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 140. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 143. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 145. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 155. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 163. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 165. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 178. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 180. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 183. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 185. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 188. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 238. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Dermatology Drugs Market, which are profiled in this report, include:
  • Allergan plc by Abbvie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Asterisk Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • DermBiont, Inc.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • GlaxoSmithkline plc
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Roivant Sciences Ltd.
  • Shinom Cosmeceuticals

Methodology

Loading
LOADING...

Table Information